Improving heart failure treatment with tailored electronic tools
Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure
This study is testing if using special electronic tools in cardiology clinics can help people with heart failure get the right medications they need to feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 4000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Emory University Academic / other |
| Locations | 4 sites (Atlanta, Georgia and 3 other locations) |
| Trial ID | NCT06847438 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the use of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) by implementing tailored electronic interventions in cardiology clinics. The approach includes utilizing an optimized checklist and clinician-facing decision support tools to promote the adoption of effective medications that have been underutilized in clinical practice. By addressing the barriers to medication adoption, the study seeks to improve patient outcomes and care quality for those suffering from heart failure. The effectiveness of these interventions will be evaluated to determine their impact on medication usage rates.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with heart failure and an ejection fraction of 40% or less.
Not a fit: Patients with heart failure types that do not require guideline-directed medical therapy, such as certain cardiomyopathies or end-stage heart failure, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and outcomes for patients with heart failure through better medication adherence.
How similar studies have performed: Other studies have shown promise in improving medication adherence through similar electronic interventions, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ejection fraction (EF) less than or equal to 40% by echocardiogram performed in the prior 18 months * Diagnosis of heart failure Exclusion Criteria: * Heart failure (HF) etiology for which GDMT is not indicated: including hypertrophic or restrictive cardiomyopathy (e.g. amyloid cardiomyopathy), constrictive pericarditis, or complex congenital heart disease * End-stage HF requiring continuous inotrope infusion, heart transplant, or left ventricular assist device * Estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m\^2 * Any conditions other than HF that are likely to alter the patient's status over 6 months, indicated by active hospice status
Where this trial is running
Atlanta, Georgia and 3 other locations
- Emory Saint Joseph's Hospital — Atlanta, Georgia, United States (Recruiting)
- Emory University Hospital Midtown — Atlanta, Georgia, United States (Recruiting)
- Emory University Hospital — Atlanta, Georgia, United States (Recruiting)
- Emory Johns Creek Hospital — Johns Creek, Georgia, United States (Recruiting)
Study contacts
- Principal investigator: Neal W Dickert, MD, PhD — Emory University
- Study coordinator: Neal W Dickert, MD, PhD
- Email: njr@emory.edu
- Phone: 404-712-6834
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.